Compare Biogen Inc (BIIB) vs eBay Inc (EBAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs eBay Inc — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while eBay Inc trades at $112.54 (market cap $49.97B). The key difference: eBay Inc is the larger of the two by market cap, and eBay Inc pays a 1.1% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | EBAY | |
|---|---|---|
Market Cap | $28.34B | $49.97B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $118.96 |
52-Week Low | $122.68 | $76.79 |
Enterprise Value | $30.62B | $53.31B |
Volume | — | 5,186,418 |
Dividend Yield | — | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
EBAY trades at $115.09, down 1.8% today, amid a bullish technical setup with strong moving average signals and key support at $114. The company shows robust profitability with a 71.79% gross margin and consistent earnings beats, while navigating a potential acquisition by GameStop. Revenue growth is steady, reaching $11.10B in 2025, though net cash flow turned negative.
Outlook remains mixed: strong fundamentals and bullish analyst sentiment (46% buy ratings) support upside, but risks include the uncertain GameStop takeover bid and competitive pressures. The stock trades above the $107.82 consensus target, suggesting limited near-term gains unless earnings surprise again.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →
